Jove
Visualize
Contact Us

Related Experiment Videos

Thalidomide in solid tumors: the London experience.

T G Eisen1

  • 1University College, London, England.

Oncology (Williston Park, N.Y.)
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The power of phase II end-points for different possible mechanisms of action of an experimental treatment.

European journal of cancer (Oxford, England : 1990)·2015
Same author

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.

British journal of cancer·2006
Same author

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same author

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma.

British journal of cancer·2004
Same author

Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest.

Melanoma research·2002
Same author

A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Thalidomide (Thalomid) showed limited efficacy in melanoma, ovarian, and breast cancers but offered encouraging results for renal-cell carcinoma. Peripheral neuropathy is a manageable side effect, with other potential adverse events also noted.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Thalidomide (Thalomid) evaluated for solid tumor treatment.
  • Investigated low-dose (100 mg nightly) and high-dose (600 mg daily) regimens.

Observation:

  • Low-dose thalidomide demonstrated disappointing responses in melanoma, ovarian, and breast cancers.
  • More encouraging results were observed in patients with renal-cell carcinoma.
  • A case study highlighted slow responses, early palliative effects distinct from antiangiogenic action, and manageable peripheral neuropathy.

Findings:

  • Thalidomide efficacy varies significantly across different solid tumors.
  • Renal-cell carcinoma showed a more promising response to low-dose thalidomide.
  • Adverse events include peripheral neuropathy, constipation, headache, edema, and rash, with management strategies available.

Related Experiment Videos

  • Anecdotal benefits reported: improved appetite, sleep, and reduced sweating.

    • Implications:

    • Thalidomide's role in solid tumor treatment requires further investigation, particularly for renal-cell carcinoma.
    • Understanding the distinct palliative effects and managing side effects are crucial for patient care.
    • Further research into thalidomide's mechanisms and optimal dosing strategies is warranted.